Adding tucatinib to first-line maintenance therapy delays disease ...
2 days ago · Based on this, the U.S. Food and Drug Administration approved this drug in 2020 for treatment of unresectable locally advanced or metastatic HER2-positive breast cancer, including …
Health Rounds: Pfizer drug delays progression of advanced breast cancer ...
21 hours ago · Pfizer’s Tukysa added to maintenance therapy significantly delayed disease progression in patients with HER2-positive metastatic breast cancer who had responded well to initial treatment ...
UC Irvine Breast Cancer Clinical Trials — Orange County, CA
Nov 26, 2025 · The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic …
TUKYSA Added to First-Line Maintenance Therapy Extends Median ...
2 days ago · TUKYSA is approved in combination with trastuzumab and capecitabine to treat adults with HER2-positive advanced unresectable or metastatic breast cancer, including patients with brain …
Orange County, CA - UCI Health
Oct 17, 2024 · Beamion BCGC-1: A Phase Ib Dose Escalation and Phase II Dose Optimization, Randomized, Open-Label, Multicenter Trial of Oral Zongertinib (BI 1810631) in Combination with …
Adding Tucatinib to First-line Maintenance Therapy Delayed Disease ...
3 days ago · Based on this, the U.S. Food and Drug Administration approved this drug in 2020 for treatment of unresectable locally advanced or metastatic HER2-positive breast cancer, including …
Study Details | NCT05879926 | Evaluating the Addition of Adjuvant ...
One increasingly utilized option is ovarian suppression, which was first reported as treatment for advanced breast cancer in 1896 and has been examined in a multitude of clinical trials over the past …
Talzenna For Metastatic Breast Cancer: A Promising Treatment Option At Uci
Treating metastatic breast cancer can be difficult, as it often requires a combination of therapies and ongoing adjustments to treatment plans. Talzenna has been approved for use in patients with HER2 …
1 in 4 metastatic breast cancer patients treated with - GlobeNewswire
3 days ago · “The latest MONALEESA analysis shows that 1 in 4 patients with metastatic disease remained progression-free for four years or more.
UCI 22-222: A Phase III, Mutlicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant versus Alpelisib Plus Fulvestrant in Patients with Hormone Receptor …